Hyderabad: Medical technology company Trivitron Healthcare manufactures and distributes products to over 170 countries. With 13 US FDA and CE certified manufacturing facilities, the company is investing in innovation in the areas of newborn screening, in-vitro diagnostics, imaging & radiology, radiation protection, critical care, and operating room solutions. Dr GSK Velu, CMD, Trivitron Healthcare shares with Telangana Today future plans of the company and potential they see in Telangana.
Plans for Telangana
Trivitron in the past has made investments into manufacturing in Tamil Nadu, Andhra Pradesh, and Maharashtra. We are seriously looking at investing in Telangana at Sultanpur Medical Devices Park (near Hyderabad). Once the Covid situation settles down, we will finalise our plans. The State has emerged as an attractive destination and the government is very proactive and there is a lot of motivation. We could look at products that will be either electronic medical equipment or those that are needed in the pharmaceuticals and biotechnology industry as the State has a large base for these industries.
We have R&D and manufacturing facilities in four countries- India, Finland, Turkey, and China. We have standalone R&D facilities in Austria and the US. We are also planning to begin manufacturing in the US in the next quarter through an acquisition. In the next 2-3 years, we will be investing through our internal accruals and post which we will explore external funding. We have 2,000 people employed in the company globally, out of which 70-80 per cent are employed in India.
We are exporting to more than 170 countries and the major markets are the US, Europe, Middle East, and Africa. We are also exporting to Japan and there is significant growth here. We also see growth opportunities in Southeast Asia and Latin America. We are catering to both developed and developing markets. Categorise-wise, in-vitro diagnostics and radiology are the key segments that are contributing to a significant part of our revenues.
In addition to in-vitro diagnostics (new-born screening and point of care diagnostics) and radiology (x-ray, ultrasound, mammography and radiation protection), the third area of focus is intensive care units with products such as ventilators, monitors and defibrillators where we will invest in manufacturing. We will also make investments in the dialysis segment in future.
Trivitron is devising different strategies for different markets. In India, we are ready to take on the top multinationals. We will get into CTMR (computed tomography/magnetic resonance), cath labs, advanced radiology and diagnostic products over the next 2-3 years. In overseas markets, we are focusing on niche markets. For instance, in the US, Europe and Japan, we are focusing on new-born screening and radiation equipment.
Trivitron quickly got into Covid-related products looking at the core need of ventilators and Covid test kits. In 2020, while the sales of conventional products took a hit, Covid products contributed to most of the revenues. In 2021, business is becoming as usual as Covid impact is reducing.
In the past five years, we have made substantial investment in R&D and manufacturing. We are in the investment mode. Until 2012, we didn’t have manufacturing revenues and post that we have shifted to become a manufacturing-led company from a trading company. We are also procuring the latest technologies from the US and Europe to develop best-in-class products.
Now you can get handpicked stories from Telangana Today on Telegram everyday. Click the link to subscribe.